Harrow (NASDAQ:HROW) Hits New 12-Month High at $47.55

Shares of Harrow, Inc. (NASDAQ:HROW) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $47.55 and last traded at $47.30, with a volume of 76879 shares. The stock had previously closed at $45.33.

Wall Street Analyst Weigh In

Several research firms have weighed in on HROW. B. Riley reissued a “buy” rating and issued a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Craig Hallum increased their price target on shares of Harrow from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Lake Street Capital increased their target price on Harrow from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, June 3rd.

Harrow Stock Performance

The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -49.47 and a beta of 0.75. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.60 and a quick ratio of 2.43. The stock’s 50-day moving average is $34.70 and its 200-day moving average is $21.87.

Harrow (NASDAQ:HROW) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. The firm had revenue of $48.94 million for the quarter, compared to the consensus estimate of $42.78 million. Analysts anticipate that Harrow, Inc. will post -0.38 EPS for the current fiscal year.

Institutional Trading of Harrow

Several institutional investors have recently made changes to their positions in HROW. nVerses Capital LLC acquired a new position in shares of Harrow in the 2nd quarter valued at about $33,000. Allspring Global Investments Holdings LLC lifted its position in Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after buying an additional 2,048 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Harrow by 66.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,745 shares of the company’s stock worth $89,000 after buying an additional 2,682 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Harrow by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock worth $248,000 after acquiring an additional 567 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new position in Harrow in the first quarter valued at about $185,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.